Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Trepo

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Antimicrobial Agents and Chemotherapy|July 17, 2013
Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis CDominique Larrey, Ansgar W Lohse, Christian Trepo, et al.
Gastroenterology|June 10, 2004
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapyBettina Werle-Lapostolle, Scott Bowden, Stephen Locarnini, et al.
Therapeutic Drug Monitoring|August 26, 2016
Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon RibavirinVéronique Loustaud-Ratti, Marianne Maynard, Sylvie Thevenon, et al.
Hepatology (Baltimore, Md.)|July 9, 2004
A phase II dose-escalating trial of clevudine in patients with chronic hepatitis BPatrick Marcellin, Herve Mommeja-Marin, Stephen L Sacks, et al.
Journal of Hepatology|December 15, 2010
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infectionMichael P Manns, Marc Bourlière, Yves Benhamou, et al.
Journal of Hepatology|March 15, 2012
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirinDominique Larrey, Ansgar W Lohse, Victor de Ledinghen, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Antimicrobial Agents and Chemotherapy|July 17, 2013
Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis CDominique Larrey, Ansgar W Lohse, Christian Trepo, et al.
Gastroenterology|June 10, 2004
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapyBettina Werle-Lapostolle, Scott Bowden, Stephen Locarnini, et al.
Therapeutic Drug Monitoring|August 26, 2016
Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon RibavirinVéronique Loustaud-Ratti, Marianne Maynard, Sylvie Thevenon, et al.
Hepatology (Baltimore, Md.)|July 9, 2004
A phase II dose-escalating trial of clevudine in patients with chronic hepatitis BPatrick Marcellin, Herve Mommeja-Marin, Stephen L Sacks, et al.
Journal of Hepatology|December 15, 2010
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infectionMichael P Manns, Marc Bourlière, Yves Benhamou, et al.
Journal of Hepatology|March 15, 2012
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirinDominique Larrey, Ansgar W Lohse, Victor de Ledinghen, et al.
Pageof 7